Read more
Cancer Vaccines as Immunotherapy of Cancer provides extensive and state-of-the-art information about the meaning, relevance and limitation of therapeutic cancer vaccines. It covers all the aspects involved in the vaccine research and development (identification of optimal target antigens, formulations, delivery strategies, adjuvants among others) as well as their use in combination with other immunomodulatory approaches.
The book discusses topics such as identification of tumor associated and specific antigens, proteogenomic for identification of novel target tumor antigens, antigen-specific T cells, and Peptide and RNA based vaccines. Additionally, it covers oncolytic viruses for antigen delivery, cancer vaccine targeting viral antigens and combinatorial immunotherapy strategies.
Written by leading experts worldwide, this is a valuable resource for cancer researchers, oncologists and members of biomedical field who wants to understand in depth the recent findings in the field of cancer vaccines.
List of contents
1. Introduction2. Identification of Tumor Associated Antigens3. Identification of Tumor Specific Antigens4. Proteogenomics for identification of novel target tumor antigens5. Antigen-specific T cells6. Tumor antigens for preventive strategies7. Peptide based vaccines8. RNA based vaccines9. Novel dendritic cells strategies10. Oncolytic viruses for antigen delivery11. Cancer vaccine targeting viral antigens12. Combinatorial immunotherapy strategies13. Conclusions
About the author
Luigi Buonaguro, PhD, is Head of Cancer Immunoregulation Unity at National Cancer Institute “Pascale” in Italy. His primary interest is the identification of novel target tumor antigens. In particular, Dr. Buonaguro is coordinating the development of a novel therapeutic cancer vaccine for liver cancer.Sjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is the exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors.Sjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is the exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors.
